Assuming that MAP Pharmaceuticals’ Levadex inhaled dihydroergotamine for the treatment of migraine receives FDA approval, Allergan will market the product to pain specialists and neurologists in the US. MAP will handle marketing to primary care physicians in the United States and will retain all rights outside the US. MAP plans to submit an NDA for Levadex by the middle of 2011. Read the company’s press release.
